Charles Schwab’s Aratana Therapeutics, Inc. PETX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2019
Q3 | – | Sell |
-117,692
| Closed | -$608K | – | 3240 |
|
|
2019
Q2 | $608K | Buy |
117,692
+26,532
| +29% | +$119K | ﹤0.01% | 2733 |
|
|
2019
Q1 | $329K | Sell |
91,160
-22,610
| -20% | -$98K | ﹤0.01% | 2917 |
|
|
2018
Q4 | $698K | Buy |
113,770
+18,460
| +19% | +$113K | ﹤0.01% | 2651 |
|
|
2018
Q3 | $557K | Buy |
95,310
+5,210
| +6% | +$26K | ﹤0.01% | 2799 |
|
|
2018
Q2 | $383K | Hold |
90,100
| – | – | ﹤0.01% | 2882 |
|
|
2018
Q1 | $398K | Buy |
90,100
+17,300
| +24% | +$77.2K | ﹤0.01% | 2792 |
|
|
2017
Q4 | $383K | Hold |
72,800
| – | – | ﹤0.01% | 2799 |
|
|
2017
Q3 | $447K | Hold |
72,800
| – | – | ﹤0.01% | 2749 |
|
|
2017
Q2 | $527K | Hold |
72,800
| – | – | ﹤0.01% | 2675 |
|
|
2017
Q1 | $386K | Hold |
72,800
| – | – | ﹤0.01% | 2736 |
|
|
2016
Q4 | $523K | Hold |
72,800
| – | – | ﹤0.01% | 2632 |
|
|
2016
Q3 | $682K | Buy |
72,800
+19,400
| +36% | +$161K | ﹤0.01% | 2515 |
|
|
2016
Q2 | $338K | Hold |
53,400
| – | – | ﹤0.01% | 2741 |
|
|
2016
Q1 | $295K | Hold |
53,400
| – | – | ﹤0.01% | 2783 |
|
|
2015
Q4 | $298K | Hold |
53,400
| – | – | ﹤0.01% | 2865 |
|
|
2015
Q3 | $452K | Sell |
53,400
-7,200
| -12% | -$122K | ﹤0.01% | 2663 |
|
|
2015
Q2 | $917K | Buy |
60,600
+8,500
| +16% | +$123K | ﹤0.01% | 2450 |
|
|
2015
Q1 | $835K | Buy |
52,100
+6,200
| +14% | +$110K | ﹤0.01% | 2446 |
|
|
2014
Q4 | $818K | Hold |
45,900
| – | – | ﹤0.01% | 2439 |
|
|
2014
Q3 | $461K | Hold |
45,900
| – | – | ﹤0.01% | 2621 |
|
|
2014
Q2 | $717K | Buy |
+45,900
| New | +$650K | ﹤0.01% | 2489 |
|
Other funds holding PETX
Charles Schwab's PETX Position: Q3 2019 in Review
Charles Schwab sold out of Aratana Therapeutics, Inc. (PETX) in Q3 2019, closing a stake of 117,692 shares — an estimated $608K sold.
Charles Schwab first reported a position in PETX in Q2 2014 and held it in 21 quarters. The position peaked at $917K in Q2 2015. 2 funds tracked by Wall St. Rank hold PETX as of Q3 2019.
- Charles Schwab reported no remaining Aratana Therapeutics, Inc. position as of Q3 2019 after selling out during the quarter.
- Charles Schwab sold 117,692 Aratana Therapeutics, Inc. shares in Q3 2019, an estimated $608K.
- Charles Schwab first reported a position in Aratana Therapeutics, Inc. in Q2 2014 and held it in 21 quarters.
- Charles Schwab's Aratana Therapeutics, Inc. position peaked at $917K in Q2 2015.
- 2 funds tracked by Wall St. Rank held Aratana Therapeutics, Inc. as of Q3 2019.
Based on Charles Schwab's 13F filing for Q3 2019, filed 8 Nov 2019.